COMPARATIVE ANALYSIS
Selank vs Semax: Research Comparison
Two Russian neuropeptides, one shared institution, divergent mechanisms. Selank is primarily anxiolytic; Semax is primarily nootropic. Their human fMRI signatures are distinct.
Selank vs Semax: Research Comparison
Selank and Semax are two Russian neuropeptides developed at the same institution — the Institute of Molecular Genetics of the Russian Academy of Sciences — and studied in overlapping but distinct research domains. Both inhibit enkephalin-degrading enzymes. Both have been tested via intranasal administration. Both have been registered in Russia. The mechanisms diverge significantly from that shared ground.
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is derived from the immunomodulatory tetrapeptide tuftsin. Its primary literature is anxiolytic — GABA-A allosteric modulation, enkephalinase inhibition, HPA axis normalization. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is derived from the ACTH(4-7) sequence. Its primary literature is nootropic and neuroprotective — BDNF upregulation via TrkB, neuroprotection in ischemia models, cognitive enhancement. The 2020 fMRI study examined both in the same healthy-human cohort and found distinct brain connectivity signatures, confirming they are not interchangeable research tools.[20]
Molecular and Mechanistic Differences Between Selank and Semax
| Property | Selank | Semax |
|---|---|---|
| Structural origin | Tuftsin analogue (Thr-Lys-Pro-Arg) + Pro-Gly-Pro | ACTH(4-7) analogue (Met-Glu-His-Phe) + Pro-Gly-Pro |
| Primary mechanism | GABA-A allosteric modulation; enkephalinase inhibition | BDNF upregulation via TrkB; neuroprotection |
| Enkephalinase IC50 | ~20 micromolar (human serum) | ~10 micromolar (human serum) |
| BDNF effects | Secondary; documented in rat hippocampus | Primary proposed mechanism |
| Primary clinical use (Russia) | Anxiolytic / nootropic | Neuroprotective / nootropic |
| fMRI connectivity signature | Right amygdala — temporal cortex | Distinct regions; different time course |
Both compounds share the Pro-Gly-Pro C-terminal extension for metabolic stability, and both inhibit enkephalin-degrading enzymes from human serum — with Semax slightly more potent at IC50 of 10 micromolar vs Selank's 20 micromolar.[17] Pentapeptide fragments of both retain inhibitory activity, suggesting the Pro-Gly-Pro extension is not required for this specific activity.
BDNF effects differ in origin: for Selank, BDNF upregulation is a secondary documented effect observed in specific models (rat hippocampus,[2] ethanol protection[8]). For Semax, it is the primary proposed mechanism across multiple model systems.
fMRI Functional Connectivity: Selank and Semax Compared
The 2020 Panikratova et al. study is the most direct human neuroimaging comparison of Selank and Semax.[20] Fifty-two healthy adults received either intranasal Selank, intranasal Semax, or placebo in a resting-state fMRI protocol. Scans were acquired at 5 minutes and 20 minutes post-administration.
Selank produced distinct changes in functional connectivity between the right amygdala and right temporal cortex regions — specifically the fusiform gyrus, inferior and middle temporal cortex, and parahippocampal gyri. These are threat-processing and contextual memory regions, consistent with the anxiolytic literature.
Semax produced a different connectivity signature — different regions, different directionality of changes, different time course. The two compounds are not pharmacologically interchangeable in their CNS activity patterns, even at the route-level where both use intranasal administration.
This fMRI data is the first direct human neuroimaging evidence that Selank has CNS activity — and that its activity pattern is distinct from Semax.
Selank vs Semax: Which Fits Which Research Model?
Research domain mapping based on the published literature:
Selank — primary candidate for:
Semax — primary candidate for:
- Neuroprotection (particularly ischemia models)
- Cognitive enhancement (primary BDNF focus)
- Learning and memory in non-anxious models
- ACTH-related signaling studies
Combined Semax and Selank Administration in Research
The 2020 fMRI study (Panikratova et al.) examined both Selank and Semax individually in the same healthy-volunteer cohort — providing the most direct neuroimaging comparison.[20] The study design allows inference about their distinct CNS signatures but was not designed as a combination-dosing protocol.
Peer-reviewed safety data for combined Selank and Semax administration is limited. The published record contains no randomized combination trial. The fMRI study demonstrates that the two compounds produce distinct connectivity signatures when given separately; this is sometimes interpreted as a basis for combination research, but published combination pharmacokinetics, interaction data, or safety profiles are not available in indexed literature.
Focus vs Anxiety: Semax and Selank Compared
The simplest characterization from the published literature: Semax for focus and neuroprotection; Selank for anxiety and stress resilience. This characterization maps to primary mechanism — ACTH/BDNF for Semax, GABA/enkephalin for Selank — and is consistent with the distinct fMRI connectivity patterns observed in healthy adults.[20]
However, the overlap is real. Selank has documented nootropic effects in learning studies[11] and BDNF upregulation.[2] Semax has enkephalinase inhibitory activity.[17] The research categories are not clean partitions. Researchers selecting between them on the basis of primary target mechanism: Selank for GABAergic/anxiolytic pathways, Semax for BDNF/neuroprotective pathways.